DOI: https://doi.org/10.18370/2309-4117.2012.6.64-69

Vaginal capsules of lactobacillus plantarum p 17630 for prevention of relapse of candida vulvovaginitis

C. Carrierо, V. Lezzі, T. Mancinі, L. Selvaggі

Abstract


An experimental multicenter prospective study of the efficacy of the drug on the basis of Lactobacillus Plantarum P 17630 as vaginal probiotics in the prevention of recurrence of VVC at 17 antenatal clinics in Italy was done. The study involved 476 women aged 18-45 years with recurrent uncomplicated VVC. The results show that the use of the treatment regimens against VVC antimycotic therapy product containing Lactobacillus Plantarum P 17630 (Gynolact) with microbiologically proven vaginal probiotic properties can significantly improve the patient outcomes.


Keywords


Lactobacillus Plantarum P 17630; prevention; recurrence; soft gelatin capsules; candida vulvovaginitis

References


Bonetci A., Mordli L.,Campominosi В., Ganora E. and Sforza P. (2003). Adherence of Lactobacillus рlantarum Р17630 in softgel capsule formulation versus Doderlein’s bacillusin tablet formulation to vaginal epithelial cells, Minerva Gynecologica 55, 279-84.

Boris S. and Barbes C. (2000). Role played by lactobacilli in controllingthe population of vaginal pathogens. Microbes and Infection 2, 543-546.

Boris S., Suarez J.E., Vazquez E. and Barbes C., (1998).Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction withuropathogens. Infection and Immunity 66, 1985-9.

Burton J.P., Cadieux P.A. and Reid G. (2003). Improved Understanding of the Bacterial Vaginal Microbiota of Women before and after Probiotik Instillation. Applied and Environmental Microbiology 69, 97-101.

Culici M., Dal Sasso M. and Braga P.C. (2004). Adhesion of Lactobacillus plantarum P17630 to vaginal epithelialcells and its influence on Candida albicans adhesion. Giornale Italiano di Microbiologia Medica Odontoiatrica e Clinica 8, 1-8.

Dho G., Marchese A. and Debbia E.A. (2003). Microbiological characteristics of Lactobacillus plantarumP17630 containined in vaginal suppositories. Giornale Italiano di Microhiobgia Medica Odontoiatrica e Clinica 7, 102-108.

Donders G.G.G., Vereecken A., Dekeersmaecker A., Van Buick B. and Spitz B. (2000). Wet mountmicroscopy reflects functional vaginallacto-bacillary flora better than Gramstain. Journal of Clinical Pathology 53, 308-313.

Falagas M.E., Betsi G.I. and Athanasiou S. (2006). Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. The Journal of Antimicrobial Chemotherapy 58, 266-272.

Foxman В., Barlow R., D’Arcy H., Gillespie B. and Sobel J.D. (2000). Candida vaginitis: selfreported incidence and associated costs. Sexually Transmitted Diseases 27, 230-235.

Foxrnan В., Marsch J.V., Gillespie B. and Sobel J.D. (1998). Frequencyand response to vaginal symptomsamong white and African American women: results of a random digit dialing survey. Journal of Womens Healthand Genderbased Medicine 7, 1167-1174.

Geiger A.M., Foxman B. and Gillespie В.W. (1995). The epidemiology of vulvovaginal candidiasis among university students. American Journalof Public Health 85, 1146-1148.

Marelli C.M.L., Rodrigues Paula C., Mazzecato T.S. and Franceschini S. (1997). Phenotype and genotype of Candida albicans strains isolated frompregnant women with recurrent vaginitis. Mycopathologia. 137, 87-94.

Marelli G., Papaleo E. and Ferrari A. (2004). Lactobacilli for prevention ofurogenital infections: a review.European Review far Medical andPharmacological Sciences 8, 87-95.

Marrazo J. (2002). Vulvovagjnalcandidiasis. British Medical Journal325, 586-587.

Mitchell H. (2004). Vaginal discharge causes, diagnoses and treatment. British Medical Journal 328:1306-1308.

Nava S., Garone G.P., Colombo D. and Mongelli L. (2002). Considerazioni sull’impiego del Lactobacillus plantarum РІ7630 nellapatologia vaginale su base infettivo infiammatoria. Rivista di Ostetricia Ginecologia Pratica e medicina perinatale 17, 14-19.

Owen M.K. and Clenney T.L.(2004). Management of vaginitis. American Family Physician 70, 2125-2132.

Patel D.A., Gillespie В., Sobel J.D., Leaman D., Nyirjesky P., Weitz V. and Foxman B. (2004). Risk factorsfor recurrent vulvovaginal candidiasis inwomen receiving maintenance antifungal therapy: Results of a prospectivecohort study. American Journal of Obstetrics and Gynecotogy 190, 644-53.

Pirotta M., Gunn J., Chondros P., Grover S., O’Malley P., Hurley S. and Garland S. (2004).Effect oflacobacillus in preventing postantibiotic vulvovaginal candidiasis: a randomized, controlled trial. British Medical Journal 329, 548-552.

Reid G. and Bruce A.W. (2003).Urogenital infections in women: canprobiotics help? Postgraduate Medical Journal 79, 428-432.

Reid G., Jass J., Sebulsky M.T. and McCormick J.K. (2004).Potential Uses of Probiotics in Clinical Practice. Clinical Microbiology Reviews 16, 658-672.

Ringdahl E.N. (2000).Treatmentof recurrent vulvovaginal candidiasis. American Family Physician 61, 3306-3312.

Sherrard J. (2001). European Guideline for the management of vaginal discharge. In: European STD guidelines. International Journal of STDand AIDS 12 (suppl 3), 73-77.

Sobel J.D. (1985). Epidemiologyand pathogenesis of recurrent vulvovaginal candidiasis. American Journalof Obstetrics and Gynecology 152,924-935.

Sobel J.D. (2002). Pathogenesis ofrecurrent vulvovaginal candidiasis. Current infectious disease reports 4,514-9.

Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A., Sperling M., LivengoodIII C., Horowitz В., Von Thron J., Libby E., Panzer H. and Teng ChiaoChu (2004). Maintenance fluconazoletherapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine 351, 876-883.

Spinillo A., Pizzoli G., Colonna L., Nicola S., De Seta F. and Guaschino S. (1993). Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstetricsand Gynecology 81,721-727.


GOST Style Citations


Bonetci A., Mordli L.,Campominosi В., Ganora E. and Sforza P. (2003). Adherence of Lactobacillus рlantarum Р17630 in softgel capsule formulation versus Doderlein’s bacillusin tablet formulation to vaginal epithelial cells, Minerva Gynecologica 55, 279-84.

Boris S. and Barbes C. (2000). Role played by lactobacilli in controllingthe population of vaginal pathogens. Microbes and Infection 2, 543-546.

Boris S., Suarez J.E., Vazquez E. and Barbes C., (1998).Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction withuropathogens. Infection and Immunity 66, 1985-9.

Burton J.P., Cadieux P.A. and Reid G. (2003). Improved Understanding of the Bacterial Vaginal Microbiota of Women before and after Probiotik Instillation. Applied and Environmental Microbiology 69, 97-101.

Culici M., Dal Sasso M. and Braga P.C. (2004). Adhesion of Lactobacillus plantarum P17630 to vaginal epithelialcells and its influence on Candida albicans adhesion. Giornale Italiano di Microbiologia Medica Odontoiatrica e Clinica 8, 1-8.

Dho G., Marchese A. and Debbia E.A. (2003). Microbiological characteristics of Lactobacillus plantarumP17630 containined in vaginal suppositories. Giornale Italiano di Microhiobgia Medica Odontoiatrica e Clinica 7, 102-108.

Donders G.G.G., Vereecken A., Dekeersmaecker A., Van Buick B. and Spitz B. (2000). Wet mountmicroscopy reflects functional vaginallacto-bacillary flora better than Gramstain. Journal of Clinical Pathology 53, 308-313.

Falagas M.E., Betsi G.I. and Athanasiou S. (2006). Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. The Journal of Antimicrobial Chemotherapy 58, 266-272.

Foxman В., Barlow R., D’Arcy H., Gillespie B. and Sobel J.D. (2000). Candida vaginitis: selfreported incidence and associated costs. Sexually Transmitted Diseases 27, 230-235.

Foxrnan В., Marsch J.V., Gillespie B. and Sobel J.D. (1998). Frequencyand response to vaginal symptomsamong white and African American women: results of a random digit dialing survey. Journal of Womens Healthand Genderbased Medicine 7, 1167-1174.

Geiger A.M., Foxman B. and Gillespie В.W. (1995). The epidemiology of vulvovaginal candidiasis among university students. American Journalof Public Health 85, 1146-1148.

Marelli C.M.L., Rodrigues Paula C., Mazzecato T.S. and Franceschini S. (1997). Phenotype and genotype of Candida albicans strains isolated frompregnant women with recurrent vaginitis. Mycopathologia. 137, 87-94.

Marelli G., Papaleo E. and Ferrari A. (2004). Lactobacilli for prevention ofurogenital infections: a review.European Review far Medical andPharmacological Sciences 8, 87-95.

Marrazo J. (2002). Vulvovagjnalcandidiasis. British Medical Journal325, 586-587.

Mitchell H. (2004). Vaginal discharge causes, diagnoses and treatment. British Medical Journal 328:1306-1308.

Nava S., Garone G.P., Colombo D. and Mongelli L. (2002). Considerazioni sull’impiego del Lactobacillus plantarum РІ7630 nellapatologia vaginale su base infettivo infiammatoria. Rivista di Ostetricia Ginecologia Pratica e medicina perinatale 17, 14-19.

Owen M.K. and Clenney T.L.(2004). Management of vaginitis. American Family Physician 70, 2125-2132.

Patel D.A., Gillespie В., Sobel J.D., Leaman D., Nyirjesky P., Weitz V. and Foxman B. (2004). Risk factorsfor recurrent vulvovaginal candidiasis inwomen receiving maintenance antifungal therapy: Results of a prospectivecohort study. American Journal of Obstetrics and Gynecotogy 190, 644-53.

Pirotta M., Gunn J., Chondros P., Grover S., O’Malley P., Hurley S. and Garland S. (2004).Effect oflacobacillus in preventing postantibiotic vulvovaginal candidiasis: a randomized, controlled trial. British Medical Journal 329, 548-552.

Reid G. and Bruce A.W. (2003).Urogenital infections in women: canprobiotics help? Postgraduate Medical Journal 79, 428-432.

Reid G., Jass J., Sebulsky M.T. and McCormick J.K. (2004).Potential Uses of Probiotics in Clinical Practice. Clinical Microbiology Reviews 16, 658-672.

Ringdahl E.N. (2000).Treatmentof recurrent vulvovaginal candidiasis. American Family Physician 61, 3306-3312.

Sherrard J. (2001). European Guideline for the management of vaginal discharge. In: European STD guidelines. International Journal of STDand AIDS 12 (suppl 3), 73-77.

Sobel J.D. (1985). Epidemiologyand pathogenesis of recurrent vulvovaginal candidiasis. American Journalof Obstetrics and Gynecology 152,924-935.

Sobel J.D. (2002). Pathogenesis ofrecurrent vulvovaginal candidiasis. Current infectious disease reports 4,514-9.

Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A., Sperling M., LivengoodIII C., Horowitz В., Von Thron J., Libby E., Panzer H. and Teng ChiaoChu (2004). Maintenance fluconazoletherapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine 351, 876-883.

Spinillo A., Pizzoli G., Colonna L., Nicola S., De Seta F. and Guaschino S. (1993). Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstetricsand Gynecology 81,721-727.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)